Title:
CASB619 INVOLVED IN COLON CANCERS
Document Type and Number:
WIPO Patent Application WO/2000/058460
Kind Code:
A2
Abstract:
CASB619 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB619 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly ovarian and colon cancers, autoimmune diseases, and related conditions.
More Like This:
Inventors:
BRUCK CLAUDINE ELVIRE MARIE (BE)
CASSART JEAN-POL (BE)
COCHE THIERRY (BE)
VINALS Y DE BASSOLS CARLOTA (BE)
CASSART JEAN-POL (BE)
COCHE THIERRY (BE)
VINALS Y DE BASSOLS CARLOTA (BE)
Application Number:
PCT/EP2000/002478
Publication Date:
October 05, 2000
Filing Date:
March 20, 2000
Export Citation:
Assignee:
SMITHKLINE BEECHAM BIOLOG (BE)
BRUCK CLAUDINE ELVIRE MARIE (BE)
CASSART JEAN POL (BE)
COCHE THIERRY (BE)
VINALS Y DE BASSOLS CARLOTA (BE)
BRUCK CLAUDINE ELVIRE MARIE (BE)
CASSART JEAN POL (BE)
COCHE THIERRY (BE)
VINALS Y DE BASSOLS CARLOTA (BE)
International Classes:
A61K31/7088; A61K39/00; A61K39/39; A61K45/00; A61K48/00; A61P35/00; C07K14/47; G01N33/50; C07K14/705; C07K16/18; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/09; C12N15/12; C12P21/02; C12Q1/02; C12Q1/68; G01N33/15; G01N33/53; G01N33/574; G01N37/00; A61K38/00; (IPC1-7): C12N15/11; C12N15/12; C07K14/705; A61K38/17; C12Q1/68; G01N33/68; C07K16/30
Domestic Patent References:
| WO1999006548A2 | 1999-02-11 | |||
| WO1995017209A1 | 1995-06-29 | |||
| WO1999054461A2 | 1999-10-28 |
Other References:
"ak13d08.s1 Soares_parathyroid_tumor_NbHPA Homo sapiens cDNA clone IMAGE:1405839 3', mRNA sequence" EMBL DATABASE ACCESSION NUMBER AA890726, 6 April 1998 (1998-04-06), XP002141255
"qo16g05.x1 NCI_CGAP_Lu5 Homo sapiens cDNA clone IMAGE:1908728 3', mRNA sequence" EMBL DATABASE ACCESSION NUMBER AI301140, 4 December 1998 (1998-12-04), XP002141256
"we72g04.x1 Soares_Dieckgraefe_colon_NHCD Homo sapiens cDNA clone IMAGE:2346678 3', mRNA sequence" EMBL DATABASE ACCESSION NUMBER AI672868, 19 May 1999 (1999-05-19), XP002141254
OHARA, O. ET AL.: "Homo sapiens mRNA for KIAA1324 protein, partial cds" EMBL DATABASE ACCESSION NUMBER AB037745, 14 March 2000 (2000-03-14), XP002141282 -& NAGASE, T. ET AL.: "Prediction of the coding sequences of unidentified human genes.XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro" DNA RES., vol. 7, February 2000 (2000-02), pages 65-73, XP000923011
"qo16g05.x1 NCI_CGAP_Lu5 Homo sapiens cDNA clone IMAGE:1908728 3', mRNA sequence" EMBL DATABASE ACCESSION NUMBER AI301140, 4 December 1998 (1998-12-04), XP002141256
"we72g04.x1 Soares_Dieckgraefe_colon_NHCD Homo sapiens cDNA clone IMAGE:2346678 3', mRNA sequence" EMBL DATABASE ACCESSION NUMBER AI672868, 19 May 1999 (1999-05-19), XP002141254
OHARA, O. ET AL.: "Homo sapiens mRNA for KIAA1324 protein, partial cds" EMBL DATABASE ACCESSION NUMBER AB037745, 14 March 2000 (2000-03-14), XP002141282 -& NAGASE, T. ET AL.: "Prediction of the coding sequences of unidentified human genes.XVI. The complete sequences of 150 new cDNA clones from brain which code for large proteins in vitro" DNA RES., vol. 7, February 2000 (2000-02), pages 65-73, XP000923011
Attorney, Agent or Firm:
Privett, Kathryn Louise (SmithKline Beecham Two New Horizons Court
Brentford Middlesex TW8 9EP, GB)
Download PDF:
Claims:
Claims
| 1. | An isolated polypeptide comprising an amino acid sequence which has at least 70% identity to the amino acid sequence of SEQ ID NO: 2 over the entire length of of SEQ ID NO: 2. |
| 2. | An isolated polypeptide as claimed in claim 1 in which the amino acid sequence has at least 95% identity to SEQ ID NO: 2. |
| 3. | The polypeptide as claimed in claim 1 comprising the amino acid sequence of SEQ ID NO: 2. |
| 4. | The isolated polypeptide of SEQ ID NO: 2. |
| 5. | A polypeptide comprising an immunogenic fragment of a polypeptide as claimed in any one of claims 1 to 4 in which the immunogenic activity of the immunogenic fragment is substantially the same as the polypeptide of SEQ ID NO: 2. |
| 6. | A polypeptide as claimed in any of claims 1 to 5 wherein said polypeptide is part of a larger fusion protein. |
| 7. | A polypeptide as claimed in any of claims 1 to 6 chemically conjugated to a carrier protein. |
| 8. | An isolated polynucleotide encoding a polypeptide as claimed in any of claims 1 to 6. |
| 9. | An isolated polynucleotide comprising a nucleotide sequence encoding a polypeptide that has at least 70% identity to the amino acid sequence of SEQ ID NO: 2, over the entire length of SEQ ID NO: 2; or a nucleotide sequence complementary to said isolated polynucleotide. |
| 10. | An isolated polynucleotide comprising a nucleotide sequence that has at least 70% identity to a nucleotide sequence encoding a polypeptide of SEQ ID NO: 2, over the entire coding region; or a nucleotide sequence complementary to said isolated polynucleotide. |
| 11. | An isolated polynucleotide which comprises a nucleotide sequence which has at least 70% identity to that of SEQ ID NO: 1 over the entire length of SEQ ID NO: 1; or a nucleotide sequence complementary to said isolated polynucleotide. |
| 12. | The isolated polynucleotide as defined in any one of claims 8 to 11 in which the identity is at least 95%. |
| 13. | An isolated polynucleotide selected from: (a) a polynucleotide comprising a nucleotide sequence encoding the polypeptide of SEQ ID NO: 2; (b) the polynucleotide of SEQ ID NO: 1; and (c) a polynucleotide obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO: 1 or a fragment thereof said polynucleotide encoding a protein which has similar immunogenic properties to those of the protein of sequence ID NO: 2 or a nucleotide sequence complementary to said isolated polynucleotide. |
| 14. | An expression vector or a recombinant live microorganism comprising an isolated polynucleotide according to any one of claims 813. |
| 15. | A host cell comprising the expression vector of claim 14 or the isolated polynucleotide of claims 8 to 13. |
| 16. | A process for producing a polypeptide of claims 1 to 7 comprising culturing a host cell of claim 15 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium. |
| 17. | A vaccine comprising an effective amount of the polypeptide of any one of claims 1 to 7 and a pharmaceutically acceptable carrier. |
| 18. | A vaccine comprising an effective amount of the polynucleotide of any one of claims 8 to 13 and a pharmaceutically effective carrier. |
| 19. | A vaccine comprising an effective amount of antigen presenting cells, modified by in vitro loading with a polypeptide of any one of claims 1 to 7, or genetically modified in vitro to express a polypeptide of claims 1 to 7 and a pharmaceutically effective carrier. |
| 20. | A vaccine as claimed in any one of claims 17 to 19 which additionally comprises a TH1 inducing adjuvant. |
| 21. | A vaccine as claimed in claim 20 in which the TH1 inducing adjuvant is selected from the group of adjuvants comprising: 3DMPL, QS21, a mixture of QS21 and cholesterol, and a CpG oligonucleotide. |
| 22. | An antibody immunospecific for the polypeptide or immunological fragment as claimed in any one of claims 1 to 5. |
| 23. | A method for screening to identify compounds which stimulate or which inhibit the function of the polypeptide of any one of claims 1 to 5 which comprises a method selected from the group consisting of : (a) measuring the binding of a candidate compound to the said polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof by means of a label directly or indirectly associated with the candidate compound; (b) measuring the binding of a candidate compound to the said polypeptide (or to the cells or membranes bearing the polypeptide) or a fusion protein thereof in the presence of a labeled competitior; (c) testing whether the candidate compound results in a signal generated by activation or inhibition of the said polypeptide, using detection systems appropriate to the cells or cell membranes bearing the polypeptide; (d) mixing a candidate compound with a solution containing a polypeptide of any one of claims 1 to 7, to form a mixture, measuring activity of the polypeptide in the mixture, and comparing the activity of the mixture to a standard; or (e) detecting the effect of a candidate compound on the production of mRNA encoding said polypeptide and said polypeptide in cells, using for instance, an ELISA assay. |
| 24. | A method for the treatment of a subject by immunoprophylaxis or therapy comprisingvo induction of immune responses to a molecule of any one of claims 1 to 5, using in vitro incubation of the polypeptide of any one of claims 1 to 7 or the polynucleotide of any one of claims 8 to 13 with cells from the immune system of a mammal, and reinfusing these activated immune cells to the mammal for the treatment of disease. |
| 25. | A method as claimed in claim 24 wherein the treatment is for ovarian or colon cancer. |
| 26. | An agonist or antagonist to the polypeptide of claims 1 to 5. |
| 27. | A compound which is: (a) an agonist or antagonist to the polypeptide of claims 1 to 5; (b) isolated polynucleotide of claims 8 to 13; or (c) a nucleic acid molecule that modulates the expression of the nucleotide sequence encoding the polypeptide of any one of claims 1 to 5; for use in therapy. |
| 28. | A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of a polypeptide of any one of claims 1 to 5 in a subject comprising analyzing for the presence or amount of said polypeptide in a sample derived from said subject. |
| 29. | A process for diagnosing a disease or a susceptibility to a disease in a subject related to expression or activity of a polynucleotide of any one of claims 8 to 13 in a subject comprising analyzing for the presence or amount of said polynucleotide in a sample derived from said subject. |
| 30. | A process for diagnosing the presence of colon cancer or a susceptibility to colon cancer in a subject related to expression or activity of a polypeptide of any one of claims 1 to 5 in a subject comprising analyzing for the presence or amount of said polypeptide in a sample derived from said subject. |
| 31. | A process for diagnosing the presence of colon cancer or a susceptibility to colon cancer in a subject related to expression or activity of a polynucleotide of any one of claims 8 to 13 in a subject comprising analyzing for the presence or amount of said polynucleotide in a sample derived from said subject. |
| 32. | An isolated polynucleotide selected from the group consisting of : (a) an isolated polynucleotide comprising a nucleotide sequence which has at least 70% identity to SEQ ID NO: 3 over the entire length of SEQ ID NO: 3; (b) an isolated polynucleotide comprising the polynucleotide of SEQ ID NO: 3; (c) the polynucleotide of SEQ ID NO: 3. |
| 33. | A live vaccine composition comprising an expression vector or recombinant live microorganism according to claim 14. |
| 34. | Use of a polynucleotide as claimed in any one of claims 8 to 13 for the manufacture of a medicament in the treatment of carcinoma. |
| 35. | Use of a polynucleotide as claimed in any one of claims 8 to 13 for the manufacture of a medicament in the treatment of colon carcinoma. |
| 36. | Use of a polypeptide as claimed in any one of claims 1 to 7 for the manufacture of a medicament in the treatment of carcinoma. |
| 37. | Use of a polypeptide as claimed in any one of claims 1 to 7 for the manufacture of a medicament in the treatment of colon carcinoma. |
Description:
INTERNATIONALSEARCHREPORT Intert-'ional ApplicationNo pc,/Ep00/02478 C.(Continuation)DOCUMENTSCONSIDEREDTOBERELEVANT Category'Citabonofdocument,wWl indicabon,whereappropnate,oftherelevantpassagesRelevanttocla
imNo. X"qo16g05. x1 NCI CGAP Lu5Homosapiens5,8, 13, cDNAcloneIMAGE: 1908728 3',mRNA32 sequence" EMBLDATABASEACCESSIONNUMBERAI301140, 4December1998(1998-12-04),XP002141256 thewholedocument AWO9517209A(SMITHKLINEBEECHAMBIOLOG17-21 ;MOMINPATRICIAMARIE(BE);GARCONNATHA) 29June1995(1995-06-29) thewholedocument X,PWO9954461A(SCHMITTARMIN;SPECHT5-18,22, THOMAS(DE);DAHLEDGAR(DE);HINZMANN27,29, BERND)28October1999(1999-10-28)32,33 seeSEQIDs11and173 claims P,X"we72gO4.x1Soares Dieckgraefe colon NHCD5,8,13 HomosapienscDNAcloneIMAGE:2346678 3', mRNAsequence" EMBLDATABASEACCESSIONNUMBERAI672868, 19May1999(1999-05-19),XP002141254 thewholedocument P,XOHARA,0.ETAL.:"HomosapiensmRNAfor5,8,13, KIAA1324protein,partialcds"32 EMBLDATABASEACCESSIONNUMBERAB037745, 14March2000(2000-03-14),XP002141282 thewholedocument -&NAGASE,T.ETAL.:"Predictionofthe codingsequencesofunidentifiedhuman genes.XVI.Thecompletesequencesof150 newcDNAclonesfrombrainwhichcodefor largeproteinsinvitro" DNARES., vol.7,February2000(2000-02),pages 65-73,XP000923011 4 In ationaiapplicationNo. INTERNATIONALSEARCHREPORTPCT/EP00/02478 Box IObservationswherecertainclaimswerefoundunsearchable(Continu
ationofitem1offirstsheet) ThisInternationalSearchReporthasnotbeenestablishedinrespecto
fcertainclaimsunderArticle17(2)(a)forthefollowingreasons: 1.a ClaimsNos.: becausetheyrelatetosubjectmatternotrequiredtobesearchedbythi
sAuthority,namely: 2.[Y]ClaimsNos.: 26 becausetheyrelatetopartsoftheInternationalApplicationthatdon
otcomplywiththeprescribedrequirementstosuch anextentthatnomeaningfulinternationalSearchcanbecarriedout,s
pecifically: The(ant)agonistofclaims26and27(a)arenotcharacterisedenoughas
to allowameaningfullsearch. 3.a ClaimsNos.: becausetheyaredependentclaimsandarenotdraftedinaccordancewit
hthesecondandthirdsentencesofRule6.4(a). Box 11Observationswhereunityofinventionislacking(Continuationofi
tem2offirstsheet) ThisInternationalSearchingAuthorityfoundmultipleinventionsin
thisinternationalapplication,asfollows: 1. As aiirequiredadditionalsearchfeesweretimelypaidbytheapplicant,
thisInternationalSearchReportcoversall searchableclaims. 2.2 As all searchabie claims could besearchedwithouteffortjustifyinganadditionalfee,thisAuthori
tydidnotinvitepayment ofanyadditionalfee. 3. 2Asonlysomeoftherequiredadditionalsearchfeesweretimelypaidby
theapplicant,thisinternationalSearchReport covers oniythoseclaimsforwhichfeeswerepaid,specificallyclaimsNos.: 4.Norequiredadditionalsearchfeesweretimelypaidbytheapplicant
.Consequently,thisInternationalSearchReportis restrictedtotheinventionfirstmentionedintheclaims;itiscovere
dbyclaimsNos.: RemarkonProtestThe additionalsearchfeeswereaccompaniedbytheapplicant'sprotest. u Noprotestaccompaniedthepaymentofadditionalsearchfees. __ FURTHER INFORMATION CONTINUED FROM PCT/ISA/210 Continuation of Box 1.2 Claims Nos.: 26 The (ant) agonist of claims 26 and 27 (a) are not characterised enough as to allow a meaningfull search.
The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1 (e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure. INTERNATIONALSEARCHREPORT Inter onal ApplicafonNo armationonpatenttamilymembers PC./EP00/02478 PatentdocumentPublication Patent family Publication citedinsearchreportdatemember(s)date WO9906548A11-02-1999AU8554798A 22-02-1999 EP1000146A 17-05-2000 WO9517209A29-06-1995AT177322T 15-03-1999 AU1316495A 10-07-1995 AU687494B 26-02-1998 AU1316695A 10-07-1995 AU705521B 27-05-1999 AU6803198A 09-07-1998 AU705519B 27-05-1999 AU6803298A 09-07-1998 CA2179779A 29-06-1995 CN1138298A 18-12-1996 DE69417063D 15-04-1999 DE69417063T 28-10-1999 WO9517210A 29-06-1995 EP0735898A 09-10-1996 EP0868918A 07-10-1998 ES2129801T 16-06-1999 GR3029750T 30-06-1999 JP9506887T 08-07-1997 NZ277802A 27-04-1998 SG49257A 18-05-1998 SI735898T 30-06-1999 ZA9410176A 17-11-1995 WO9954461A28-10-1999DE19817948A 21-10-1999